HC Wainwright Reaffirms Buy Rating for Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 119.06% from the company’s previous close. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2028 earnings at $2.51 EPS.

Several other research firms also recently commented on ZVRA. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target on the stock. JMP Securities started coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price objective for the company. Finally, Roth Mkm upped their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $9.13 on Wednesday. The company’s 50-day moving average is $8.12 and its two-hundred day moving average is $6.59. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.30. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm has a market capitalization of $487.36 million, a price-to-earnings ratio of -4.69 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the previous year, the business posted ($0.40) EPS. Analysts forecast that Zevra Therapeutics will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ZVRA. International Assets Investment Management LLC lifted its holdings in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics in the 1st quarter valued at about $64,000. The Manufacturers Life Insurance Company grew its stake in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares during the period. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics in the 3rd quarter valued at $92,000. Finally, XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at about $94,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.